Courbevoie
Présidente du directoire deTROPHOS, entreprise de développement pharmaceutique.
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in a pivotal clinical study for Spinal Muscular Atrophy (substantially funded by the AFM patient association). Olesoxime is also ready for a phase II proof of concept study in Multiple Sclerosis (MS) disease progression. A second product, TRO40303, is in phase II clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare).
Trophos, founded in 1999, is based in Marseille, France and currently has 27 employees.
Expériences précédentes : Ernst & Young, Gemplus (Gemalto), start up
Mes compétences :
Droit
Finances
